News

A review of university-investor links has been published, commissioned by Research England from Mike Rees, former deputy group CEO of Standard Chartered, start-up commercialisation expert and angel investor.  Research England asked Mike Rees, former deputy group CEO of Standard Chartered, to review ways to strengthen university access to finance that supports spin-out company formation and university-investor relationships. The review focused on universities with large-scale investor links and those seeking support through schemes, such as the Research England Connecting Capability Fund (CCF). The Rees Review listened to advice from a broad range of stakeholders, through more than 90 interviews, and drew evidence from a data report by Tomas Coates Ulrichsen (Centre for Science, Technology and Innovation (CSTI) Policy, University of Cambridge), also commissioned by Research England. 

The Intellectual Property Rights (IPR) Services Framework is a national agreement available to members of NEUPC, LUPC, SUPC, APUC, NWUPC, HEPCW. The IPR Services framework agreement gives members of NEUPC, LUPC, SUPC, APUC, NWUPC, HEPCW access to suppliers who can provide legal advice and guidance, licensing and registration services on all matters relating to the creation, development and production of patents, trademarks, copyright, design rights, trade secrets and intellectual property rights. NEUPC will be holding supplier review meetings with all the approved suppliers on the intellectual property rights (IPR) services framework from Monday 29th to Wednesday 31st July and would appreciate feedback on the IPR framework via a short survey.  The survey allows you to rate suppliers on various aspects of framework activity, including communication, pricing and tender responses.  The survey will close on Friday 26th July.

WHERE SCIENCE MEETS BUSINESS Falling Walls Venture is a global platform for the most promising research-based start-ups nominated by academic institutions from across the world. We provide a stage for pioneering founders who have turned science into business, creating entrepreneurial solutions for today’s most pressing challenges. The fast-paced pitch event is part of the 2-day Falling Walls Conference.

In vitro platform for retinal toxicity assessment and disease modelling Newcells Biotech Ltd. has developed an in vitro model of the retinal pigmented epithelium, to assess the safety and efficacy of novel ocular compounds. This technology could better predict the outcome in the human eye and reduce the number of animals used to assess the toxicity of ocular drugs. An end-user pharmaceutical company, able to provide access to ocular compounds and data with known in vivo/in vitro toxicity profiles, is sought to validate the model.